Impact of Sleep Deprivation and Caffeine in Medical Professionals
NCT ID: NCT04273841
Last Updated: 2025-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
7 participants
INTERVENTIONAL
2017-07-06
2024-07-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real-Time Caffeine Optimization During Total Sleep Deprivation
NCT04399083
Sleep Deprivation Study
NCT05560620
Enhancing Operational Performance in Healthy Rested Soldiers With Pharmacological Stimulants
NCT03893032
Characterization of Fatigue in Military Personnel With Traumatic Brain Injuries
NCT03998358
Nutrition Intervention to Promote Immune Recovery From Sleep Restriction
NCT03525184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Caffeine Group
This group will receive caffeine gum.
Military Energy Gum
Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.
Placebo
This group will receive gum without caffeine.
Placebo Gum
Pellet form placebo gum
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Military Energy Gum
Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.
Placebo Gum
Pellet form placebo gum
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Intermediate group - National Capital Area PGY-2 and 3 residents in internal medicine
3. Expert group-Board certified internists from National Capital Area
Exclusion Criteria
* Self-reported nighttime lights-out times earlier than 2100 hours on average during weeknights (Sunday through Thursday) (Post-consent Checklist)
* Self-reported morning wake-up times later than 0900 on average during weekdays (Monday through Friday) (Post-consent Checklist)
* Self-reported habitual napping (\> 4 time a week in conjunction with normal sleep habits) (Post-consent Checklist)
* Self-reported caffeine use in excess of 400 mg (e.g., approximately 8 caffeinated sodas or 4 12-oz cups of coffee) per day on average (Post-consent Checklist; document provides exclusionary limits for various caffeinated products).
* Score of lower than 31 or higher than 69 on the Morningness-Eveningness Questionnaire (MEQ form)
* Score of 14 or above on the Beck Inventory Form (BDI form)
* Score of 41 or above on the Spielberger Trait Anxiety Inventory
* History of cardiovascular disease (to include but not limited to arrhythmias, valvular heart disease, congestive heart failure, history of sudden cardiac death or myocardial infarction) (Medical History and Examination Form)
* History of neurologic disorder (to include, but not limited to epilepsy or another seizure disorder, amnesia for any reason, hydrocephalus, MS, narcolepsy or other sleep disorders) (Medical History and Examination form; sleep items on Post-Consent Checklist)
* Underlying pulmonary disease requiring daily inhaler use (Medical History and Examination form)
* Kidney disease or kidney abnormalities (Medical History and Examination form, laboratory results)
* Liver disease or liver abnormalities (Medical History and Examination form, laboratory results)
* Self-reported history of psychiatric disorder requiring hospitalization or psychiatric product for any length of time (Medical History and Examination form)
* Self-reported or suspected regular nicotine use or addiction, defined as more than 1 cigarette or equivalent per week, within the last 1 year (Medical History and Examination form)
* Self-reported or suspected heavy alcohol use; minimum limit to define heavy alcohol use is 14 drinks per week or as determined by the examining study licensed physician (Medical History and Examination form)
* Self-reported or suspected use of products or drugs that cannot be safely discontinued during in-laboratory phases, to be determined on a case-by-case basis by the examining study licensed physician (Medical History and Examination form)
* Self-reported or suspected current use of other illicit drugs, to include but not limited to benzodiazepines, amphetamines, cocaine, marijuana (Medical History and Examination form)
* Positive urine pregnancy result
* Female volunteers who are breastfeeding, lactating, or actively trying to conceive
* Resting blood pressure above 140/90 or resting pulse \> 110 (Medical History and Examination form). Note that if a repeat measurement is within range then the volunteer will not be excluded.
* BMI ≥ 30 (Obese Class I or greater) (Medical History and Examination form)
* Clinically significant values (as determined by the reviewing study licensed physician) for any hematology or chemistry parameter. Reviewing physician may opt to repeat any clinically significant tests and include volunteers whose repeat test values are not clinically significant.
* Positive urine nicotine/cotinine result during screening visit (NicCheck™ I test strip results)
* Positive urine drug result during screening visit
* Any use of prescription or over-the-counter sleep aids during the 6 month period prior to screening indicative of a potential sleep disorder as determined by the examining study medical investigator \[e.g., use of a sleep aid for several nights following time zone travel, or the occasional use of a sleep inducing medication (e.g. 1-2 times per month), would not necessarily constitute evidence of a sleep disorder and result in disqualification\].
* Not fitting into one of four categories: 1) 3rd of 4th year medical student AND native English speaker, 2) medical intern, 3) PGY-2 or PGY-3 resident in internal medicine, 4) board-certified internist (Post-consent checklist)
* Inability to read and sign the consent and HIPAA authorization form
* Active duty military or federal personnel: not off duty and not on approved annual leave for the enrollment visit as well as the in-laboratory phase of the study
Related to FMRI task.
* The presence of incompatible shrapnel or implanted devices
* A history of prior inability to complete an MRI scan due to anxiety or claustrophobia (participants will not be able to take benzodiazepines or other sedatives prior to the scan to treat anxiety, as these would adversely impact thought processes).
* Being treated with calcium channel blocker medicines (because of the potential impact of such medicines on cerebral blood flow patterns).
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Walter Reed Army Institute of Research (WRAIR)
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
WRAIR Sleep Research Center
Silver Spring, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WRAIR #2311
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.